PGAP1 Activators
Chemical activators of PGAP1 work through various mechanisms to modulate the function and activity of this protein, which is involved in the remodeling of glycosylphosphatidylinositol (GPI) anchors on proteins. Sphingosine-1-phosphate, for instance, activates sphingosine-1-phosphate receptors that may lead to lipid raft clustering and subsequent activation of PGAP1. Cholesterol is a critical component of these lipid rafts and can facilitate the correct localization and function of GPI-anchored proteins, thereby activating PGAP1. Similarly, β-Cyclodextrin and Methyl-β-cyclodextrin function by extracting cholesterol from cell membranes, thereby altering the lipid raft domains and activating PGAP1. Filipin III also targets cholesterol but does so by binding directly to it, disrupting the lipid rafts and potentially activating PGAP1. The statins, including Simvastatin, Mevastatin, and Lovastatin, inhibit HMG-CoA reductase, leading to lower cholesterol biosynthesis, which in turn can modify the lipid raft microdomains and activate PGAP1.
Other chemicals act on different aspects of the lipid metabolic pathways. Manumycin A inhibits Ras farnesyltransferase, which can affect membrane composition and dynamics, thus activating PGAP1. Fumonisin B1 inhibits ceramide synthase, leading to changes in sphingolipid metabolism, which can also result in the activation of PGAP1. Myriocin, by inhibiting serine palmitoyltransferase, leads to altered sphingolipid levels, which can activate PGAP1 through changes in membrane dynamics. Lastly, ceramide itself, by forming stable structures within cell membranes, may activate PGAP1 by affecting the environment of GPI-anchored proteins, facilitating their interaction with PGAP1 and promoting its remodeling activity. Each of these chemical activators, through distinct interactions with lipid biosynthesis or membrane composition, can contribute to the activation of PGAP1, affecting the processing of GPI-anchored proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine-1-phosphate receptors which in turn can lead to the activation of PGAP1 through downstream signaling pathways involving lipid raft clustering and modulating GPI-anchored protein function. | ||||||
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $27.00 $2809.00 $129.00 $210.00 $583.00 $88.00 | 11 | |
Cholesterol, as a major component of lipid rafts, can facilitate the correct localization and function of GPI-anchored proteins, thereby activating PGAP1 by promoting its interaction with these proteins in the lipid rafts. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A inhibits Ras farnesyltransferase, potentially leading to alterations in cell membrane composition and dynamics that can activate PGAP1 by enhancing its access to GPI-anchored substrates. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Fumonisin B1 inhibits ceramide synthase, which can lead to disruptions in sphingolipid metabolism, potentially activating PGAP1 by causing compensatory changes in GPI-anchor remodeling. | ||||||
β-Cyclodextrin | 7585-39-9 | sc-204430 sc-204430A | 25 g 500 g | $60.00 $538.00 | 3 | |
β-Cyclodextrin extracts cholesterol from membranes, which can activate PGAP1 by altering the lipid raft environments where GPI-anchored proteins reside, enhancing the remodeling activity of PGAP1. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $118.00 $148.00 | 26 | |
Filipin III binds to cholesterol, disrupting lipid rafts and potentially activating PGAP1 by promoting the redistribution and clustering of GPI-anchored proteins that are substrates for PGAP1. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
Myriocin is a potent inhibitor of serine palmitoyltransferase, leading to altered sphingolipid levels and potentially activating PGAP1 through changes in membrane dynamics affecting GPI-anchor processing. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin inhibits HMG-CoA reductase, leading to reduced cholesterol biosynthesis, which can activate PGAP1 by modifying the lipid raft microdomains essential for GPI-anchored protein function. | ||||||
Methyl-β-cyclodextrin | 128446-36-6 | sc-215379A sc-215379 sc-215379C sc-215379B | 100 mg 1 g 10 g 5 g | $20.00 $48.00 $160.00 $82.00 | 19 | |
Methyl-β-cyclodextrin extracts cholesterol from the plasma membrane, potentially activating PGAP1 by inducing changes in the distribution and function of GPI-anchored proteins which PGAP1 modifies. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Mevastatin, similar to simvastatin, inhibits HMG-CoA reductase affecting cholesterol synthesis and can activate PGAP1 by changing the lipid raft composition thus influencing GPI-anchor remodeling. | ||||||